Seagen, Astellas report positive results from PADCEV phase 2 trial in advanced urothelial cancer

This article was originally published here

The cohort is evaluating the antibody-drug conjugate PADCEV (enfortumab vedotin-ejfv) for patients with locally advanced or metastatic urothelial cancer who have been previously treated with a PD-1/L1 inhibitor

The post Seagen, Astellas report positive results from PADCEV phase 2 trial in advanced urothelial cancer appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply